CCNG1 encodes cyclin G1, a cell cycle regulator involved in growth control and cellular proliferation. As a cyclin-dependent protein kinase regulator, CCNG1 modulates G1/S and G2/M phase transitions and functions as an intermediate through which p53 mediates its anti-proliferative effects 1. CCNG1 expression is regulated by multiple microRNAs (miR-23b, miR-27b, miR-325, miR-503) and epigenetic modifications, with dysregulation implicated in cancer progression and other diseases. In prostate cancer, CCNG1 is overexpressed (69% of cases), and miR-23b/27b-mediated CCNG1 suppression enhances apoptosis when combined with flutamide 2. In gastric cancer, CCNG1 repression by miR-27b increases P53 stability, activating the miR-508-5p/ABCB1 axis to reverse multidrug resistance 3. In colorectal cancer, PRMT6 epigenetically represses CCNG1 expression to promote proliferation 4. CCNG1 is also targeted by miR-503 in mesothelioma as an oncogenic pathway 5 and regulated by the lncRNA MSC-AS1/miR-325 axis in diabetic nephropathy 6. CCNG1 expression in the reproductive axis correlates with estrous cycling and follicle development 1. Clinically, CCNG1 serves as a biomarker in breast cancer development, with DeltaRex-G (a CCNG1 inhibitor) emerging as a potential therapeutic agent 7.